Allergan Plc is no longer looking at selling its women’s health business, Chief Executive Officer Brent Saunders said on Tuesday.
“For Women’s Health, we have concluded that the highest value proposition for this business at this time is to continue managing it and optimizing it,” Saunders said.
Saunders also said the company’s anti-infectives business will “more likely than not” be sold over the near term.
The company had said in May it was looking to sell both its women’s health and infectious disease units following a review of its businesses.
By Tamara Mathias
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).